List view / Grid view
22 June 2015 | By Victoria White
The European Commission has approved Bristol-Myers Squibb’s Opdivo, a PD-1 immune checkpoint inhibitor, for the treatment of advanced melanoma in adults...
19 June 2015 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb has announced results from new post hoc analyses of the Phase 3b AVERT and AMPLE trials, which included early moderate to severe rheumatoid arthritis (RA) patients with active disease and markers of poor prognosis...
10 June 2015 | By Victoria White
Bristol-Myers Squibb has announced that data from the Orencia Phase 3b AVERT and AMPLE trials will be presented in during the EULAR 2015...
4 June 2015 | By Victoria White
UK patients with rheumatoid arthritis now have more choice for managing their condition with the launch of the ClickJect Pre-Filled pen...
3 June 2015 | By Victoria White
Results from an interim analysis of the Phase III ELOQUENT-2 trial of elotuzumab in combination with lenalidomide and dexamethasone have been announced...
2 June 2015 | By Victoria White
The FDA has accepted the supplemental Biologics License Application for Opdivo+Yervoy regimen in patients with previously untreated advanced melanoma...
1 June 2015 | By Victoria White
BMS has announced positive results of a Phase III trial evaluating the Opdivo+Yervoy regimen in patients with previously untreated advanced melanoma...
22 May 2015 | By Victoria White
The CHMP has adopted a positive opinion recommending that nivolumab be granted approval for the treatment of NSCLC after prior chemotherapy in adults...
7 May 2015 | By
A 7-year study of a Nulojix regimen has demonstrated a significant relative risk reduction of death or transplant failure over a cyclosporine regimen...
30 April 2015 | By Victoria White
The FDA has accepted for filing and review the sBLA for Opdivo for the treatment of previously untreated patients with unresectable or metastatic melanoma...
27 April 2015 | By Victoria White
CHMP has adopted a positive opinion, approving BMS’ ClickJect Pre-Filled Pen for use in adult patients with moderate to severe active rheumatoid arthritis...
27 April 2015 | By Victoria White
Primary endpoints were successfully met in a Phase III clinical trial evaluating a 12-week daclatasvir-based regimen for the treatment of patients with HCV...
24 April 2015 | By Victoria White
ELPA has launched ‘C: My Journey’, an online resource where people diagnosed with HCV can go to find out more about the condition and how to get support...
24 April 2015 | By Victoria White
The CHMP has adopted a positive opinion recommending that Bristol-Myers Squibb’s Opdivo be granted approval for use in patients with advanced melanoma...
20 April 2015 | By Victoria White
Results are positive from a Phase II trial evaluating the Opdivo+Yervoy regimen versus Yervoy alone in patients with previously untreated advanced melanoma...
